248 related articles for article (PubMed ID: 28771657)
1. Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials.
Nast A; Dilleen M; Liyanage W; Aikman L; Szczypa P; Dressler C
Br J Dermatol; 2018 Feb; 178(2):400-405. PubMed ID: 28771657
[TBL] [Abstract][Full Text] [Related]
2. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
4. Cost Per Additional Responder Associated With Ixekizumab and Etanercept in the Treatment of Moderate-to-Severe Psoriasis.
Feldman SR; Foster SA; Zhu B; Burge R; Al Sawah S; Goldblum OM
J Drugs Dermatol; 2017 Dec; 16(12):1246-1252. PubMed ID: 29240860
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
6. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
[TBL] [Abstract][Full Text] [Related]
8. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Puig L; Dossenbach M; Berggren L; Ljungberg A; Zachariae C
Acta Derm Venereol; 2019 Oct; 99(11):971-977. PubMed ID: 31240322
[TBL] [Abstract][Full Text] [Related]
9. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
10. A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study.
de Vries AC; Thio HB; de Kort WJ; Opmeer BC; van der Stok HM; de Jong EM; Horvath B; Busschbach JJ; Nijsten TE; Spuls PI
Br J Dermatol; 2017 Mar; 176(3):624-633. PubMed ID: 27416891
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
Bagel J; Tyring S; Rice KC; Collier DH; Kricorian G; Chung J; Iles J; Stolshek BS; Kaliyaperumal A; Papp KA
Br J Dermatol; 2017 Aug; 177(2):411-418. PubMed ID: 28196270
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
Gottlieb AB; Lacour JP; Korman N; Wilhelm S; Dutronc Y; Schacht A; Erickson J; Zhang L; Mallbris L; Gerdes S
J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):679-685. PubMed ID: 27696577
[TBL] [Abstract][Full Text] [Related]
13. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
[TBL] [Abstract][Full Text] [Related]
14. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
[TBL] [Abstract][Full Text] [Related]
18. Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.
Atalay S; van den Reek JMPA; van Vugt LJ; Otero ME; van de Kerkhof PCM; den Broeder AA; Kievit W; de Jong EMGJ
BMC Dermatol; 2017 May; 17(1):6. PubMed ID: 28482858
[TBL] [Abstract][Full Text] [Related]
19. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab.
Torii H; Sato N; Yoshinari T; Nakagawa H;
J Dermatol; 2012 Mar; 39(3):253-9. PubMed ID: 22211581
[TBL] [Abstract][Full Text] [Related]
20. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]